395 related articles for article (PubMed ID: 36544769)
1. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
Luo H; Song G; Wang D; Li M; Dai N
Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
10. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Liao PF; Wang PY; Peng TR
Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
14. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
15. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
17. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
Qian D; Xu Y; Wu Y; Qiu J; Hong W; Meng X
Chin Med J (Engl); 2023 Jul; 136(14):1663-1670. PubMed ID: 37279392
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
